{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-349160","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2026-08-13T20:06:44+00:00","discovered_at":"2026-08-13T20:09:04.456747+00:00","generated_at":"2026-08-13T20:09:29.388849+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"4DMT Q2 net loss $72.9M; 4D-150 Phase 3 enrollment complete, $200M credit facility","bullets":["Net loss $72.9M vs $54.7M; R&D expenses $68.3M vs $48.0M; G&A $12.5M vs $11.5M.","Cash $430.6M at June 30, 2026, down from $514.0M; funds into H2 2028.","4D-150 4FRONT-1 topline Q2 2027 (N=523); 4FRONT-2 enrollment complete, topline H2 2027.","PRISM 2-yr data: 78% treatment burden reduction overall, 87% in recently diagnosed; no new inflammation.","$200M Hercules credit facility, initial draw $20M; DME Phase 3 to start Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-349160","json":"https://secwatch.observer/filing/0001193125-26-349160.json","markdown":"https://secwatch.observer/filing/0001193125-26-349160.md","text":"https://secwatch.observer/filing/0001193125-26-349160.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/0001193125-26-349160-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:09:29.388849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}